Literature DB >> 22699414

Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients.

Ismail Kocyigit1, Mehmet Gungor Kaya, Ozcan Orscelik, Coskun Kaya, Mahmut Akpek, Halid Zengin, Murat Hayri Sipahioglu, Aydin Unal, Mahmut Ilker Yilmaz, Bulent Tokgoz, Oktay Oymak, Jonas Axelsson.   

Abstract

BACKGROUND/AIMS: Cardiovascular disease is the main cause of morbidity and mortality in autosomal-dominant polycystic kidney disease (ADPKD) patients. To clarify temporal relationship between ADPKD, hypertension and the loss of renal function, we examined these factors in patients with early-stage ADPKD who did not yet have hypertension.
METHODS: Fifty patients with ADPKD (42% males, 36.6 ± 9.9 years, no blood pressure medication) and 50 healthy controls (44% males, 35.4 ± 6.4 years) were studied cross-sectionally. Pulse wave velocity (PWV), cardiac morphology and function, aortic elastic indexes, estimated glomerular filtration rate (eGFR), 24-hour ambulatory blood pressure, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and highly sensitive C-reactive protein (hs-CRP) were measured in all participants, using conventional methods.
RESULTS: Despite a normal blood pressure, aortic stiffness index and pulse wave velocity values were increased in patients compared to controls (6.8 ± 4.7 vs. 5.1 ± 3.3, p = 0.043 and 9.6 ± 1.3 vs. 5.8 ± 1.1 m/s, p < 0.001). In univariate analysis, IL-6, TNF-α, hs-CRP and eGFR were all significantly correlated with PWV. The independence of these correlations were analyzed in a regression model, and showed PWV to be significantly predicted by IL-6, TNF-α and hs-CRP.
CONCLUSION: Increased arterial stiffness and pulse wave velocity are early manifestations of ADPKD appearing before hypertension or reduced eGFR. However, these vascular abnormalities are related to signs of systemic low grade inflammation, suggesting a common pathophysiological mechanism apparently present also in other vascular diseases but yet to be elucidated.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699414     DOI: 10.1159/000339440

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  18 in total

1.  Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function.

Authors:  Cuma Bulent Gul; Abdulmecit Yildiz; Alparslan Ersoy; Serdar Kahvecioglu; Burak Asiltas; Fatih Yildirim; Selime Ermurat; Saim Sag; Aysegul Oruc; Sumeyye Gullulu; Mustafa Gullulu
Journal:  Int Urol Nephrol       Date:  2015-06-06       Impact factor: 2.370

2.  Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease.

Authors:  Kristen L Nowak; Heather Farmer; Melissa A Cadnapaphornchai; Berenice Gitomer; Michel Chonchol
Journal:  Nephrol Dial Transplant       Date:  2017-02-01       Impact factor: 5.992

3.  The association of endothelin-1 levels with renal survival in polycystic kidney disease patients.

Authors:  Ismail Kocyigit; Eray Eroglu; Ahmet Safa Kaynar; Derya Kocer; Seval Kargi; Gokmen Zararsiz; Ruslan Bayramov; Hakan Imamoglu; Murat Hayri Sipahioglu; Bulent Tokgoz; Munis Dundar; Oktay Oymak
Journal:  J Nephrol       Date:  2018-07-18       Impact factor: 3.902

4.  Endothelial nitric oxide synthase gene expression is associated with hypertension in autosomal dominant polycystic kidney disease.

Authors:  Ismail Kocyigit; Serpil Taheri; Elif Funda Sener; Aydin Unal; Eray Eroglu; Fahir Öztürk; Kezban Korkmaz; Gokmen Zararsiz; Hakan Imamoglu; Murat Hayri Sipahioglu; Bulent Tokgoz; Oktay Oymak
Journal:  Cardiorenal Med       Date:  2014-12-10       Impact factor: 2.041

5.  Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease.

Authors:  Ismail Kocyigit; Eray Eroglu; Ozcan Orscelik; Aydin Unal; Ozkan Gungor; Fahir Ozturk; Cigdem Karakukcu; Hakan Imamoglu; Murat Hayri Sipahioglu; Bulent Tokgoz; Oktay Oymak
Journal:  J Nephrol       Date:  2014-02-11       Impact factor: 3.902

6.  Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?

Authors:  Asmin Andries; Kristien Daenen; François Jouret; Bert Bammens; Djalila Mekahli; Ann Van Schepdael
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

7.  Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Kristen L Nowak; Wei Wang; Heather Farmer-Bailey; Berenice Gitomer; Mikaela Malaczewski; Jelena Klawitter; Anna Jovanovich; Michel Chonchol
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-18       Impact factor: 8.237

8.  Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.

Authors:  Alexandros Briasoulis; Raymond Oliva; Rigas Kalaitzidis; Colleen Flynn; Ivana Lazich; Carrie Schlaffer; George Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-30       Impact factor: 3.738

9.  Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Johannes Leierer; Paul Perco; Benedikt Hofer; Susanne Eder; Alexander Dzien; Julia Kerschbaum; Michael Rudnicki; Gert Mayer
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923

10.  The Effect of Smoking on Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease Patients with Preserved Renal Function.

Authors:  Cuma Bulent Gul; Abdulmecit Yildiz; Saim Sag; Aysegul Oruc; Alparslan Ersoy; Sumeyye Gullulu
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.